Health & Medical Cancer & Oncology

FDA Panel: Avastin Not for Breast Cancer

FDA Panel: Avastin Not for Breast Cancer

FDA Panel: Avastin Not for Breast Cancer


Advisory Panel Votes 12-1 to Reverse Avastin's Approval as a Breast Cancer Drug

July 20, 2010 -- Avastin is not helpful in the treatment of metastatic breast cancer, and the drug's approval for this use should be withdrawn.

That's the verdict of an FDA advisory panel, whose 12-1 vote urges the FDA to remove breast cancer from the list of approved uses of the Genentech drug. The vote is specific to breast cancer and does not affect Avastin's approval for the treatment of colon, lung, brain, or kidney cancer.

Against the advice of a previous advisory committee, the FDA in 2008 gave Avastin "accelerated approval" for the treatment of spreading breast cancer, in combination with chemotherapy. As a condition of that approval, Genentech agreed to conduct two new clinical trials.

Those trials showed no evidence that Avastin offered an overall benefit to breast cancer patients. In contrast, the drug added significantly to the side effects of chemotherapy.

Avastin is a man-made antibody that blocks the chemical signals that tumors use to grow new blood vessels. By preventing the growth of new blood vessels, the drug starves tumors.

But clinical trials showed little evidence that breastcancer patients benefit by adding Avastin to chemotherapy. The drug increased the rate at which these patients experienced serious side effects.

Briefing documents prepared for the panel by FDA staff painted a dim picture, suggesting Avastin's risks outweigh its benefits.

But Genentech noted that Avastin did not shorten patient survival, and that the drug should be tried in more patients with metastatic breast cancer in order to find out how it might best be used. Far from withdrawing its earlier approval, Genentech argued, the FDA should grant Avastin full approval for a wider group of patients.

The FDA is not bound by the decisions of its advisory panels, which are made up of experts drawn from outside the FDA. However, it's rare for the federal agency to buck a panel's near-unanimous decision.


Get Your Personalized Breast Cancer Treatment Report
SHARE
RELATED POSTS on "Health & Medical"
Greed Is Good? Cigars and Throat Cancer
Greed Is Good? Cigars and Throat Cancer
Top 7 Breast Cancer Sites
Top 7 Breast Cancer Sites
Newer Breast Cancer Drugs Aid Survival
Newer Breast Cancer Drugs Aid Survival
Mammograms Spot Cancers That May Not Be Dangerous
Mammograms Spot Cancers That May Not Be Dangerous
Aging, Frailty, and Chemotherapy
Aging, Frailty, and Chemotherapy
Pediatric Supportive Care (PDQ®): Supportive care - Patient Information [NCI]-Overview
Pediatric Supportive Care (PDQ®): Supportive care - Patient Information [NCI]-Overview
Information About Breast Cancer Treatment
Information About Breast Cancer Treatment
Many Consumers Don't Understand Sunscreen Labels, Study Finds
Many Consumers Don't Understand Sunscreen Labels, Study Finds
pictures of skin cancer
pictures of skin cancer
CML Treatment and Clinical Trials
CML Treatment and Clinical Trials
How to Diagnose Malignant Melanoma
How to Diagnose Malignant Melanoma
Management of Castration-Resistant Prostate Cancer
Management of Castration-Resistant Prostate Cancer
Symptoms of Skin Cancer
Symptoms of Skin Cancer
Red Wine Antioxidant Fights Cancer
Red Wine Antioxidant Fights Cancer
How Effectively Combination Chemotherapy Works?
How Effectively Combination Chemotherapy Works?
Colon Cancer is Preventable - Don't Die From This Disease!
Colon Cancer is Preventable - Don't Die From This Disease!
Colon Health Check - Self Test For Early Colon Cancer Detection
Colon Health Check - Self Test For Early Colon Cancer Detection
Brachytherapy
Brachytherapy
Brain Cancer and Gliomas
Brain Cancer and Gliomas
Sheryl Crow's Battle with Breast Cancer
Sheryl Crow's Battle with Breast Cancer

Leave Your Reply

*